Last reviewed · How we verify
NCT01336920
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Phase 1 trial testing carfilzomib in Adult Nasal Type Extranodal NK/T-cell Lymphoma in 15 participants. Completed in 1 March 2018.
1 April 2015
Quick facts
| Lead sponsor | University of Nebraska |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 21 June 2011 |
| Primary completion | 1 April 2015 |
| Estimated completion | 1 March 2018 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- carfilzomib (carfilzomib) — full drug profile →
Conditions studied
- Adult Nasal Type Extranodal NK/T-cell Lymphoma — all drugs for Adult Nasal Type Extranodal NK/T-cell Lymphoma →
- Anaplastic Large Cell Lymphoma — all drugs for Anaplastic Large Cell Lymphoma →
- Angioimmunoblastic T-cell Lymphoma — all drugs for Angioimmunoblastic T-cell Lymphoma →
- Peripheral T-cell Lymphoma — all drugs for Peripheral T-cell Lymphoma →
Sponsor
University of Nebraska
Who can join
19 and older, any sex, with Adult Nasal Type Extranodal NK/T-cell Lymphoma or Anaplastic Large Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase I trial studies the side effects and best dose of carfilzomib in treating patients with relapsed or refractory T-cell lymphoma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Advances in targeted therapy for malignant lymphoma.
Wang L, Qin W, Huo YJ, Li X, et al · · 2020 · cited 88× · PMID 32296035 · DOI 10.1038/s41392-020-0113-2 -
A Review of New Findings in Adult T-cell Leukemia-Lymphoma: A Focus on Current and Emerging Treatment Strategies.
Hermine O, Ramos JC, Tobinai K. · · 2018 · cited 61× · PMID 29411267 · DOI 10.1007/s12325-018-0658-4 -
Therapeutic options in peripheral T cell lymphoma.
Zhang Y, Xu W, Liu H, Li J. · · 2016 · cited 31× · PMID 27071634 · DOI 10.1186/s13045-016-0267-0 -
Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors.
Pakjoo M, Ahmadi SE, Zahedi M, Jaafari N, et al · · 2024 · cited 24× · PMID 38331801 · DOI 10.1186/s12964-023-01433-5 -
Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and management.
Bennani-Baiti N, Ansell S, Feldman AL. · · 2016 · cited 15× · PMID 26581318 · DOI 10.1586/17474086.2016.1122514 -
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.
Nooka A, Gleason C, Casbourne D, Lonial S. · · 2013 · cited 13× · PMID 23386784 · DOI 10.2147/btt.s24580 -
Immune targeted therapy for diffuse large B cell lymphoma.
Zheng Y, Si J, Yuan T, Ding S, et al · · 2021 · cited 6× · PMID 35402846 · DOI 10.1097/bs9.0000000000000095 -
Genetic alterations in systemic nodal and extranodal non-cutaneous lymphomas derived from mature T cells and natural killer cells.
Boi M, Stathis A, Zucca E, Inghirami G, et al · · 2012 · cited 5× · PMID 22568409 · DOI 10.1111/j.1349-7006.2012.02321.x
Verify or expand the search:
- PubMed search for NCT01336920
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of carfilzomib
Trials testing the same drug.
- NCT05017545 — Carfilzomib and Belatacept for Desensitization · Phase 1, PHASE2 · active not recruiting
- NCT03275285 — Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Rel · Phase 3 · completed
- NCT02293109 — Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma · Phase 1 · completed
- NCT01738594 — Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma · Phase 1 · terminated
- NCT01246063 — Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refr · Phase 1, PHASE2 · completed
Other University of Nebraska trials
Trials by the same sponsor.
- NCT07507006 — Feasibility Study of the Flash-Sole: A Wearable Midsole With Soft Actuators for Walking Assistance · NA · not yet recruiting
- NCT07517705 — MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma · NA · not yet recruiting
- NCT07506993 — Inflammation in Clear Aligners With and Without Attachments · not yet recruiting
- NCT07207850 — Parents Helping Parents for Youth Vaping Cessation · NA · not yet recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01336920 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Nebraska
- Last refreshed: 15 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01336920.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing